A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
CONTEXT: As many as 1 in every 110 children in the United States has an autism spectrum disorder (ASD). Many medical treatments for ASDs have been proposed and studied, but there is currently no consensus regarding which interventions are most effective. OBJECTIVE: To systematically review evidence regarding medical treatments for children aged 12 years and younger with ASDs. METHODS: We searched the Medline, PsycInfo, and ERIC (Education Resources Information Center) databases from 2000 to May 2010, regulatory data for approved medications, and reference lists of included articles. Two reviewers independently assessed each study against predetermined inclusion/exclusion criteria. Studies of secretin were not included in this review. Two reviewers independently extracted data regarding participant and intervention characteristics, assessment techniques, and outcomes and assigned overall quality and strength-of-evidence ratings on the basis of predetermined criteria. RESULTS: Evidence supports the benefit of risperidone and aripiprazole for challenging and repetitive behaviors in children with ASDs. Evidence also supports significant adverse effects of these medications. Insufficient strength of evidence is present to evaluate the benefits or adverse effects for any other medical treatments for ASDs, including serotonin-reuptake inhibitors and stimulant medications. CONCLUSIONS: Although many children with ASDs are currently treated with medical interventions, strikingly little evidence exists to support benefit for most treatments. Risperidone and aripiprazole have shown benefit for challenging and repetitive behaviors, but associated adverse effects limit their use to patients with severe impairment or risk of injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“citalopram has demonstrated poor tolerability and no benefit for repetitive behaviour in children with ASD 208 .”
From Autism spectrum disorder (2020) · cites this paper as [208]
In the citing paper
“Although these drugs serve to manage challenging and repetitive behaviors, they have little effect on the social communication deficit observed in ASD 88 .”
From Progress toward treatments for synaptic defects in autism (2013) · cites this paper as [88]
In the citing paper
“These two agents, Risperdal and Abilify (11), do not target the core symptoms, but rather treat a cluster of associated symptoms referred to as irritability.”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [11]
In the citing paper
“Therefore, therapeutic efficacy is currently evaluated by improvement in the diagnostic behavioral symptoms (11, 50, 95).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [11]
In the citing paper
“Dysfunction in the dopamine system in ASD has been suggested, based on the beneficial effects of dopamine receptor antagonists (for example, antipsychotic drugs such as risperidone) in treating certain symptoms commonly exhibited by affected individuals, such as stereotypies, aggression, hyperactivity, and self-injury [123].”
From Social “wanting” dysfunction in autism: neurobiological underpinnings and treatment implications (2012) · cites this paper as [123]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Educating Children with Autism
Lord, C. (2001) · Cited by 1,499
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Cited by
Items 201–300 of 355
Hanson, E. M., Sideridis, G. D., Jackson, F. I., Porche, K. M., Campe, K. L., & Huntington, N. L. (2015) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2015.09.004 · Cited by 17
“Measurement of change or improvement in RRB also is desired in assessing the efficacy of medical (McPheeters et al., 2011), psychopharmacological (Hollander et al., 2005b), educational. behavioral, and other therapeutic interventions (Dawson et al., 2010).”
BackgroundMedical Care Burden of Children with Autism Spectrum Disorders
Lin, J. (2014) · Review Journal of Autism and Developmental Disorders · doi:10.1007/s40489-014-0023-8 · Cited by 15
“McPheeters et al. (2011) also reported that although many of the children with ASDs are currently treated with medical interventions, strikingly little evidence exists to support the benefit of most of these treatments.”
BackgroundWeiner, R. H., & Greene, R. L. (2013) · EXPLORE · doi:10.1016/j.explore.2013.10.005 · Cited by 13
Kirsten, T. B., Casarin, R. C. V., Bernardi, M. M., & Felício, L. F. (2019) · Biology Open · doi:10.1242/bio.041327 · Cited by 13
“Pioglitazone is an anti-diabetic drug that is authorized by the FDA to treat type 2 diabetes mellitus (insulin sensitizing effect) (Hanefeld and Belcher, 2001).”
BackgroundStem Cells for Improving the Treatment of Neurodevelopmental Disorders
Donegan, J. J., & Lodge, D. J. (2020) · Stem Cells and Development · doi:10.1089/scd.2019.0265 · Cited by 14
Kasahara, Y., Yoshida, C., Nakanishi, K., Fukase, M., Suzuki, A., & Kimura, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-74662-0 · Cited by 15
Newspaper Coverage of Autism Treatment in Canada: 10-Year Trends (2004–2013)
Lanovaz, M. J., Dufour, M., & Shah, S. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000706 · Cited by 13
Clinical Approach in Autism: Management and Treatment
Riesgo, R. D. S., Gottfried, C., & Becker, M. M. (2013) · InTech eBooks · doi:10.5772/54784 · Cited by 15
“Others RCT didn’t show strengths of evidence for effect of citalopram or escitalopram to reduce repetitive or challenging behavior (McPheeters et al., 2011).”
BackgroundLouw, K.-A., Bentley, J., Sorsdahl, K., & Adnams, C. M. (2013) · Journal of Child & Adolescent Mental Health · doi:10.2989/17280583.2013.767265 · Cited by 11
“Recent reviews concluded that most of the psychotropic medications used to treat children with ASD lack sufficient evidence (Huffman et al. 2011, McPheeters et al. 2011, Warren et al. 2011b, Siegel and Beaulieu 2012).”
BackgroundDosing and Monitoring: Children and Adolescents.
Hirsch, G. S. (2018) · Europe PMC (PubMed Central) · Cited by 11
Park, J., Shin, S., Kim, J., Park, K. C., & Park, J. H. (2016) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.10891 · Cited by 11
Kim, H., Park, E. J., Kim, J.-H., Boon‐yasidhi, V., Tarugsa, J., Reyes, A., Manalo, S. G., & Joung, Y. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0152 · Cited by 14
“Moreover, a recent systematic review of risperidone provided moderate evidence that the drug ameliorated stereotyped behaviors, but no evidence of improvements of social or communicative function (McPheeters et al. 2011).”
Dalton, G. D., Siecinski, S. K., Nikolova, V. D., Cofer, G. P., Hornburg, K. J., Qi, Y. P., Johnson, G. A., Jiang, Y., Moy, S. S., & Gregory, S. G. (2024) · Behavioral and Brain Functions · doi:10.1186/s12993-024-00240-3 · Cited by 10
“Currently, antipsychotic drugs (e.g., aripirazole, risperidone) are used to alleviate ASD irritability, but these drugs are not consistently effective and have many adverse side effects [7, 8].”
BackgroundMining and modeling human genetics for autism therapeutics
Smith, D. G., & Ehlers, M. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.03.004 · Cited by 10
“These atypical antipsychotics are associated with adverse effects including sedation, weight gain and metabolic disorders, and extrapyramidal symptoms [11].”
BackgroundOdds of fussy eating are greater among children with obesity and anxiety
Þorsteinsdóttir, S., Ólafsdóttir, A. S., Brynjólfsdóttir, B., Bjarnason, R. G., & Njarðvík, U. (2021) · Obesity Science & Practice · doi:10.1002/osp4.548 · Cited by 10
“obesity, dyslipidemia, insulin resistance, alteration of metabolism, and systemic inflammation.(4,48,50) Psychotropic medications have also been associated with increased liver disease severity in pediatric non‐alcoholic fatty liver disease.”
BackgroundAnixt, J. S., Meinzen‐Derr, J. K., Estridge, H., Smith, L., & Brinkman, W. B. (2018) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0000000000000561 · Cited by 12
van Andel, D. M., Sprengers, J. J., Keijzer‐Veen, M. G., Schulp, A. J. A., Lillien, M. R., Scheepers, F. E., & Bruining, H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.780281 · Cited by 17
“This measure was chosen because it is a commonly used outcome scale in (neuro)behavioral trials (50) and because we hypothesized that a beneficial clinical effect of bumetanide in this population would become evident by reducing behavioral reactivity to sensory stimuli.”
MethodHam, A., Chang, A. Y., Li, H., Bain, J., Goldman, J. E., Sulzer, D., Veenstra-VanderWeele, J. M., & Tang, G. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02741-z · Cited by 17
“Available medications primarily target co-occurring symptoms, e.g., attention de fi cit and hyperactivity, irritability, and agitation [7, 8].”
Self-citationLevitskiy, D., Confair, A., Wagner, K. E., DeVita, S., Shea, N., McKernan, E. P., Kopec, J., Russo, N. N., Middleton, F. A., & Hicks, S. D. (2021) · Research in Autism · doi:10.1016/j.rasd.2021.101788 · Cited by 12
Liu, Q., Mi, J., Du, Y., Rong, Z., Qin, Y., Jiang, W., Li, X., Yu, J., Yang, L., Du, X., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8098 · Cited by 9
“While existing pharmaceuticals like risperidone and aripiprazole have been approved by FDA to relieve ASD symptoms, they do not address the core symptoms of the condition and may actually exacerbate them (King et al., 2009; McPheeters et al., 2011).”
BackgroundBo, M., Carta, A., Cipriani, C., Cavassa, V., Simula, E. R., Huyền, N. T. T., Phan, G. T. H., Noli, M., Matteucci, C., Sotgiu, S., et al. (2024) · Microorganisms · doi:10.3390/microorganisms13010009 · Cited by 11
“Risperidone and aripiprazole, both atypical antipsychotics, have been FDA-approved for the treatment of irritability and aggression in children with ASD [130].”
Schizophrenia in Autistic People with Intellectual Disabilities. Treatment and Interventions
Bakken, T. L., Hellerud, J. M. A., Kildahl, A. N., Solheim‐Inderberg, A. M., Hove, O., & Helverschou, S. B. (2024) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-024-06286-6 · Cited by 11
“They may be particularly sensitive to side effects, such as tardive dyskinesia (Fodstad et al., 2010) and others (Downs et al., 2017; McPheeters et al., 2011 ).”
Challenge and Potential for Research on Gene-Environment Interactions in Autism Spectrum Disorder
Wender, C. L. A., & Veenstra-VanderWeele, J. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-49227-8_9 · Cited by 9
Self-citationFive-Year Follow-up of Preschoolers with Autism and Comorbid Psychiatric Disorders
Kim, J. J., Freeman, S. F. N., Paparella, T., & Forness, S. R. (2012) · Behavioral Disorders · doi:10.1177/019874291203800105 · Cited by 10
“A particular focus was on psychotropic medication, given recent evidence of potential efficacy of various psychopharmacologic treatments in young children with ASD (Gleason et al., 2007; Konopasek & Forness, in press; Luby, 2009; McDougle, Stigler, Erikson, & Posey, 2008; McPheeters et al., 2011).”
BackgroundA Systematic Review of the MDMA Model to Address Social Impairment in Autism
Chaliha, D. R., Mamo, J. C. L., Albrecht, M. A., Lam, V., Takechi, R., & Vaccarezza, M. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210101130258 · Cited by 8
“These are controversial for use, due to their adverse effects [16, 17].”
BackgroundOpoku, M. P., Moustafa, A., Anwahi, N., Shah, H., Aldhaheri, S., Almeqbaali, A., Alkateri, T., & Belbase, S. (2023) · The Linacre Quarterly · doi:10.1177/00243639231156701 · Cited by 8
“Understanding that most autistic children live with comorbid conditions and as such, are on medications whose side effects could lead to obesity (McPheeters et al. 2011; Myers and Johnson 2007; Siegel and Beaulieu 2012).”
BackgroundSystematic review of the effectiveness of homoeopathy in the treatment of autism spectrum disorder
Saxena, V., Chacko, G., & Saxena, U. (2021) · Clinical Archives of Communication Disorders · doi:10.21849/cacd.2021.00339 · Cited by 10
“It comes from the indications that long term usage of allopathic medication, in case of persisting symptoms (which is very common in ASD), may cause side-effects and induce drug-dependency which may not be safe for this population especially when they cannot express their problem [19-21].”
BackgroundPérisse, D., Guinchat, V., Hellings, J. A., & Baghdadli, A. (2011) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2011.10.011 · Cited by 13
Utilization of Complementary and Alternative Therapies in Youth with Developmental Disabilities
Tenenbaum, R. B., Agarwal, R., Cooke, M. S., Agrawal, M. M., Maddux, M., & Burke, S. L. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/3630509 · Cited by 7
Sharma, R., Tiwari, A., Rahi, S., & Mehan, S. (2020) · Current Psychopharmacologye · doi:10.2174/1389203721999200820165117 · Cited by 6
Nazari, G., Mousavi, M., & Sadeghi‐Firoozabadi, V. (2023) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs-121995 · Cited by 9
“Considering the adverse effects of most medical interventions suggested for ASD and their questioned benefit for treating patients’ symptoms (5), behavioral and psycho-educational management strategies have been suggested and are currently considered the gold-standard treatment of ASD (6).”
BackgroundReview of Pharmacogenomics of Psychiatric Comorbidities in Autism Spectrum Disorder
Pedrero, A. Á., Bote, V., Lamborena, C., Medina, R., Serra-Llovich, A., Amaia Hervas, G., & Arranz, M. J. (2023) · Pharmacogenomics · doi:10.2217/pgs-2023-0134 · Cited by 7
Evans, P., Golla, S., & Morris, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00018-8 · Cited by 8
Attention Deficit Hyperactivity Disorder (ADHD) in Children with Autism Spectrum Disorders
Antshel, K. M., & Hier, B. O. (2013) · Springer eBooks · doi:10.1007/978-1-4614-4788-7_53 · Cited by 8
Cravero, C., Guinchat, V., Claret, A., Sahnoun, C., Bonniau, B., Bodeau, N., Danion-Grilliat, A., Cohen, D., & Chamak, B. (2017) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2016.10.002 · Cited by 9
Mammarella, V., Randazzo, L., Romano, S., Breda, M., & Bruni, O. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2508277 · Cited by 9
“Some of these compounds, namely atypical antipsychotics, often show adverse effects on sleep, mainly insomnia or hypersomnolence [35].”
Becker, M. M., Bosa, C. A., Freitas, V. L. D. O., Goldim, J. R., Ohlweiler, L., Roesler, R., Schwartsmann, G., & Riesgo, R. D. S. (2016) · Jornal de Pediatria · doi:10.1016/j.jped.2015.08.012 · Cited by 5
Hernández‐Arteaga, E., Candia, J. A. C., Pluma-Romo, R., Solís-Meza, M. I., Villafuerte-Vega, M. N., & Guevara, F. A. (2025) · Neuroglia · doi:10.3390/neuroglia6020018 · Cited by 6
“Speci fi cally, antipsychotics, such as aripiprazole and risperidone, are considered effective for managing irritability and aggression [75,76].”
Autism Spectrum Disorders: The Worldwide Charm and Challenge of Autism Spectrum Disorders
Johnson, E. B. (2014) · Advances in special education · doi:10.1108/s0270-401320140000027004 · Cited by 4
Li, X., Einfeld, S., Stancliffe, R. J., & Hodge, M. A. (2025) · Journal of Intellectual & Developmental Disability · doi:10.3109/13668250.2024.2446215 · Cited by 5
“…of medical treatments for children with individual diagnoses of autism and intellectual disability (e.g., antipsychotic medications) have benefits in reducing behaviour towards normative expectations, they are not without significant adverse effects (McPheeters et al., 2011; McQuire et al., 2015).”
Turgeon, M. C. D. M., Tremblay, É., Déry, N., & Guay, H. (2013) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2013.11.005 · Cited by 7
Hyde, J., & García‐Rill, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817992-5.00006-4 · Cited by 5
Lee, S., Hwang, S., Nam, H.-S., Cho, J.-S., & Chung, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.891227 · Cited by 4
Pharmacological Interventions for Adults with Autism Spectrum Disorder
Rotta, K., VanDerwall, R., Ehrhardt, K. E., & Poling, A. D. (2022) · Autism and child psychopathology series · doi:10.1007/978-3-030-98507-3_17 · Cited by 4
Perumal, N., Balan, N., & Stanfield, A. C. (2013) · International Journal of Developmental Disabilities · doi:10.1179/2047386912z.00000000016 · Cited by 4
“A systematic review of medical treatments for children with autism spectrum disorders by McPheeters et al. (2011) concluded that risperidone and aripiprazole have shown benefit for challenging and repetitive behaviours, but associated adverse effects limit their use to patients with severe…”
BackgroundCommunality between Obsessive Compulsive Disorder and Autism Spectrum Disorders
Bejerot, S., Weizman, A., & Gross‐Isseroff, R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-4788-7_32 · Cited by 10
Harrington, J. W., & Bora, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35868-2.00008-6 · Cited by 5
Hyperbaric oxygen therapy for autism spectrum disorder (ASD) in children and adults
Xiong, T., Chen, H., Luo, R., & Mu, D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010922 · Cited by 5
Kim, B.-U., Kim, H., Park, E. J., Kim, J.-H., Boon‐yasidhi, V., Tarugsa, J., Reyes, A., Manalo, S. G., & Joung, Y. (2022) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2022.0004 · Cited by 4
“Also, in a systematic review of risperidone, there was no significant change in social or communicative function, although it effectively reduced stereotypy (McPheeters et al. 2011).”
Davias, A., Lyon-Caen, S., Iszatt, N., Monot, C., Rayah, Y., Ilhan, Z. E., Guichardet, K., Bayat, S., Valmary‐Degano, S., Muckle, G., et al. (2025) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2025.101063 · Cited by 7
“Therapies, apart from early-life behavioral interventions, are often limited (Dawson and Burner, 2011; McPheeters et al., 2011).”
Cardiovascular Pharmacology in Pediatric Patients with Congenital Heart Disease
Dabbagh, A., Talebi, Z., & Rajaei, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-10442-8_4 · Cited by 4
Medication Management of Childhood OCD
Ivarsson, T., Skarphéðinsson, G., & Weidle, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811427-8.00009-5 · Cited by 3
Bernier, R., & Dawson, G. (2016) · Wiley eBooks · doi:10.1002/9781119125556.devpsy303 · Cited by 31
Pervin, M. M., Hansmann, N. M., & Hagmayer, Y. (2024) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-023-06223-z · Cited by 3
“…by the National Standards Project (NSP) and the National Professional Development Center (NPDC) (Wong et al., 2015) and a systematic review of medical treatments for children with ASD (McPheeters et al., 2011 Participants were asked to tick a box when they currently used the type of treatment.”
InfluentialAnalysis of Autism: A Perspective from Behavioral Modification
Borja, G., Guallichico, G., & Luna, A. (2025) · Lecture notes in networks and systems · doi:10.1007/978-3-031-87701-8_36 · Cited by 3
Mendes, E. H. F., & Freitas, J. M. D. R. (2025) · Revista Contemporânea · doi:10.56083/rcv5n6-093 · Cited by 2
Zare, S., Reihani, H., Sarvestani, R. T., Inaloo, S., Nemati, H., & Asadi‐Pooya, A. A. (2025) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-025-06936-3 · Cited by 2
Predictors of Psychotropic Medication Use Among Autistic Adults
Mahé, O., Morel‐Kohlmeyer, S., Briend, F., & Houy‐Durand, E. (2025) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-025-06966-x · Cited by 3
Bruni, O., Mammarella, V., Breda, M., Gringras, P., Malow, B. A., Schaer, M., Schroder, C. M., & Weiss, S. K. (2026) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2026.102286 · Cited by 3
Development of the Observable Behaviors of Autism Spectrum Disorder Scale
Deal, L. S., DeMuro, C., DiBenedetti, D. B., & Lewis, S. (2017) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479016680258 · Cited by 2
“Many children with autism are treated with pharmaceutical therapies; however, there is little evidence to support a clinical benefit for most of these treatments.(18,19) While numerous existing measures are available to diagnose and stage the severity of ASD, none of these tools are designed to assess treatment benefi…”
BackgroundCardiovascular Pharmacology in Pediatric Patients with Congenital Heart Disease
Dabbagh, A., Talebi, Z., & Rajaei, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-44691-2_4 · Cited by 2
Postoperative Central Nervous System Management in Patients with Congenital Heart Disease
Dabbagh, A., & Ramsay, M. A. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-44691-2_37 · Cited by 2
Medical cannabis in autism spectrum disorder: a specialist perspective
Erridge, S., Sodergren, M. H., & Rucker, J. (2022) · British Journal of Neuroscience Nursing · doi:10.12968/bjnn.2022.18.5.232 · Cited by 2
Mu-Suppression Neurofeedback Training Targeting the Mirror Neuron System: A Pilot Study
Dastgheib, S. S., Wang, W., Kaufmann, J. M., Moratti, S., & Schweinberger, S. R. (2024) · Applied Psychophysiology and Biofeedback · doi:10.1007/s10484-024-09643-4 · Cited by 4
“…medical therapy is mainly reduced to treating symptoms, and the affected individuals usually end up taking multiple medications, often with disturbing side effects, even though no prescription has been approved for the core symptoms of autism so far (McPheeters et al., 2011; Pandina et al., 2020).”
BackgroundMechanistic perspective on the actions of vitamin a in autism spectrum disorder etiology
Carrazana‐Escalona, R., Espinoza, F., & Ávila, A. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.07.012 · Cited by 2
Li, Y. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1604937 · Cited by 4
Coury, D. L. (2011) · Evidence-Based Mental Health · doi:10.1136/ebmh.2011.100112 · Cited by 2
A Systematic Review of Secretin for Children With Autism Spectrum Disorders
Mack, A. H. (2012) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/j.ypsy.2011.08.100 · Cited by 2
Melmed, R. D., & Cubells, J. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-18096-0_121 · Cited by 3
Reflections on Clinical Trials in Fragile X Syndrome
Jønch, A. E., & Jacquemont, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00020-2 · Cited by 2
Veatch, O. J., Butler, M. G., Elsea, S. H., Malow, B. A., Sutcliffe, J. S., & Moore, J. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239029 · Cited by 2
Alshawwa, S. Z., Alarnous, R., & Albasalah, A. (2023) · Periodicals of Engineering and Natural Sciences (PEN) · doi:10.21533/pen.v11i2.3506 · Cited by 3
“Mcpheeters et al., 2011 examined the use of CAM for ASD children, the result of the study indicated that 50%– 75% of ASD children use CAM.”
BackgroundResultda Costa, L. N., Herzog, M. V. M., Santos, M. J. G. F., dos Santos, A. D. E., Tsugao, P. S., Marin, B. T., Mas, B. A. D., Martins, V. D. S., Malveira, L. L., Celestino, H. D. O., et al. (2023) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2023v5n4p1989-2000 · Cited by 3
Is it clinically defensible to treat children longer term with second generation antipsychotics?
Hazell, P. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1479741 · Cited by 2
Big data approaches to investigating Child Mental Health disorder outcomes
Downs, J. M. (2018) · Research Portal (King's College London) · Cited by 2
Listik, E., & Listik, M. (2020) · medRxiv · doi:10.1101/2020.10.17.20214437 · Cited by 2
“(Imran et al. 2011) Moreover, there were no clinical studies to observe a new 228 pharmacological approach or family orientation for this disease (McPheeters et al. 2011; 229 Patterson et al. 2012).”
BackgroundAUTISM AWARENESS IN PARENTS IN THE AGE OF DIGITAL MEDIA (A CRITICAL STUDY)Preprint
Shabbir, T., Ali, Z., Arif, I., Uddin, S., Abbasi, S., & Abro, M. U. R. (2021) · OSF Preprints (OSF Preprints) · doi:10.17605/osf.io/fzb3w · Cited by 4
Emerging Research towards the Understanding and Treatment of Autism
Wang, P. P., Hammond, R., Postma, F. R., & Healy, A. M. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00384 · Cited by 1
Ponnou, S., Briffault, X., Thomé, B., Aragno, V., & Chamak, B. (2025) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2025.02.006 · Cited by 1
Folefack, A. I., Djiogue, S., Beppe, G. J., Allah-Doum, N. G., Nange, A. C., Tadah, R. N. D., Barga, B. M., Atsama, P. M., Sadou, W., & Bum, E. N. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20251274 · Cited by 1
Garg, H., Pandey, A. K., Anushree, N., Garg, S., & Mohan, K. R. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.104838 · Cited by 1
Waterhouse, L. H. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-415961-7.00001-0 · Cited by 2
Jaarsma, P. (2014) · Linköping University Electronic Press eBooks · doi:10.3384/diss.diva-104418 · Cited by 4
“31 McPheeters et al. (2011) conducted a systematic review of medical treatments for children with Autism Spectrum Disorder.”
BackgroundTranslational Neuroimaging for Drug Discovery and Development in Autism Spectrum Disorders
Badura, L. L., Saxe, M., Risterucci, C., Brammer, M. J., McTighe, S. M., Ring, R. H., & Smith, D. G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-386945-6.00009-3 · Cited by 3
Brief outline on neurobiology of autistic spectrum disorders (ASD)
Rani, K. (2018) · Journal of Applied Biotechnology & Bioengineering · doi:10.15406/jabb.2018.05.00119 · Cited by 1
“There are also alternative medication which are chosen by some of physicians includes opiate antagonist, immunotherapy, hormonal agents, megavitamins and other dietary supplements [19,20].”
BackgroundPostoperative Central Nervous System Management in Patients with Congenital Heart Disease
Dabbagh, A., & Ramsay, M. A. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-10442-8_44 · Cited by 1
Mustary, K., & Reed, P. (2025) · Social Sciences & Humanities Open · doi:10.1016/j.ssaho.2025.101564 · Cited by 3
Early Signs and Early Intervention
Freitag, C. M. (2015) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000363613 · Cited by 1
The Medical Treatment of Autism Disorders
Dodig‐Ćurković, K., Ćurković, M., & Radić, J. (2013) · InTech eBooks · doi:10.5772/52832 · Cited by 3
“These results showed that also it was a greater rise in prolactin levels in subjects in the risperidone compared with those in the placebo althought they did not report clinical events such as gynecomastia or galactorrhoea, that could be elevated prolactin levels [33].”
ResultAntipsychotics Medication Use and its Metabolic Challenges for Autism Spectrum Disorders
García, G. (2012) · North American Journal of Medicine and Science · doi:10.7156/v5i3p162 · Cited by 1
“Of note, none of the studies published in recent reviews provided information on the use of more than one antipsychotic in children with ASD.(10,13)”
BackgroundResultWhat Do Parents of Children With Autism Spectrum Disorders Think
Thompson, C. C. (2014) · ProQuest LLC eBooks · Cited by 1
Spectrum of Neurodegeneration in Autism Spectrum Disorder
Rani, K. (2018) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-5282-6.ch016 · Cited by 1
Scheithauer, M. C., Muething, C., Gerencser, K. R., & Call, N. A. (2019) · Autism and child psychopathology series · doi:10.1007/978-3-030-20843-1_32 · Cited by 1
Intervention Strategies for Children with Autism Spectrum Disorder
Baer, M. (2015) · Cited by 2
Becker, M. M., Bosa, C. A., Freitas, V. L. D. O., Goldim, J. R., Ohlweiler, L., Roesler, R., Schwartsmann, G., & Riesgo, R. D. S. (2016) · Jornal de Pediatria (Versão em Português) · doi:10.1016/j.jpedp.2016.02.004 · Cited by 2
Patel, T. (2023) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.510
Kirsten, T. B. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.10.2012.tde-25072013-142030 · Cited by 6
Transtornos do espectro autista: progredindo para melhorias em sua farmacoterapia
Suzuki, Â. M. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.41.2013.tde-26072013-144026 · Cited by 1
Behavioral Treatment for Children with Autism
Peng-Wilford, P., & Kong, X. (2011) · North American Journal of Medicine and Science · doi:10.7156/v4i3p158 · Cited by 1
Scahill, L. D., Tillberg, C. S., & Martin, A. (2014) · Wiley eBooks · doi:10.1002/9781118911389.hautc23 · Cited by 1
Metadata
- Authors
- McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J.
- Affiliations
- Vanderbilt University (US)
- ORCID
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2011-05-01
- Volume
- 127
- Issue
- 5
- Pages
- e1312-e1321
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2121150539
- Cited by
- 356
- References
- 55
- Citations by year
- 2026: 4 · 2025: 18 · 2024: 16 · 2023: 16 · 2022: 19 · 2021: 17 · 2020: 23 · 2019: 22 · 2018: 27 · 2017: 28 · 2016: 20 · 2015: 28 · 2014: 25 · 2013: 42 · 2012: 41
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PEDIATRICS (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- autism spectrum disorder, medical treatment, children, risperidone, aripiprazole, behavioral problems, repetitive behavior, adverse effects, serotonin reuptake inhibitors, stimulant medication, antipsychotic drugs, quality of evidence
- MeSH terms
- Aripiprazole, Child, Child Development Disorders, Pervasive, Child, Preschool, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluoxetine, Humans, Male, Patient Compliance, Piperazines, Prognosis, Serotonin Antagonists, Severity of Illness Index, Antipsychotic Agents, Citalopram, Quinolones, Randomized Controlled Trials as Topic, Treatment Outcome, Risperidone, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.